Synergy CHC Corp. Seeks Shareholder Approval for Massive Dilution, Distressed Financing, and Reverse Stock Split to Avoid Delisting

summarizeSummary

Synergy CHC Corp. is seeking shareholder approval for highly dilutive equity plan expansion and a distressed warrant issuance, alongside a reverse stock split to avoid Nasdaq delisting, all against a backdrop of significant financial losses.

check_boxKey Events

• Massive Equity Incentive Plan Expansion

  Shareholders are asked to approve an amendment to the 2024 Equity Incentive Plan, increasing the aggregate number of shares available for issuance to 35,000,000. This represents a potential dilution of over 236% to the current 14,781,883 outstanding shares. The amendment also permits the repricing of outstanding awards without further shareholder approval.

• Distressed Lender Warrant Issuance Approval

  The company seeks approval for the full issuance of 3,000,000 shares upon exercise of a Lender Warrant at an exercise price of $0.00001 per share. This is required to comply with Nasdaq Listing Rules 5635(b) and 5635(d) due to the issuance exceeding 20% of outstanding shares and being below the minimum price. Failure to approve could trigger an Event of Default under the Credit Agreement.

• Proposed Reverse Stock Split to Avoid Delisting

  Shareholders will vote on a reverse stock split at a ratio of up to 1-for-40. The primary purpose is to regain compliance with Nasdaq's minimum bid price rule (Rule 5550(a)(2)) and avoid potential delisting, indicating significant market challenges.

• Annual Meeting Agenda

  In addition to the capital structure changes, the annual meeting agenda includes routine proposals such as the election of five directors and the ratification of RBSM LLP as the independent registered public accounting firm for fiscal year 2026.

auto_awesomeAnalysis

Synergy CHC Corp. is presenting several critical proposals to shareholders that collectively signal severe financial distress and a precarious future. The company is seeking approval to significantly expand its equity incentive plan, potentially authorizing the issuance of up to 35,000,000 shares, which represents over 236% potential dilution to current shareholders. This proposal also includes the ability to reprice outstanding awards, a move often viewed negatively as it can protect executives from stock price declines at shareholder expense. Concurrently, the company is asking for approval to issue 3,000,000 shares upon the exercise of a Lender Warrant at a nominal price of $0.00001 per share, representing approximately 20.3% dilution. This approval is crucial to comply with Nasdaq listing rules and avoid an Event of Default under a credit agreement, highlighting a distressed financing situation. Furthermore, the company proposes a reverse stock split at a ratio of up to 1-for-40, a measure typically undertaken by companies facing delisting from Nasdaq due to a low share price. These actions, combined with the previously disclosed substantial net loss of $12.34 million for fiscal 2025, material weaknesses in internal controls, and a major customer (Costco) reducing business, indicate a company struggling for survival and facing significant challenges to its capital structure and market listing.